Heat shock proteins (HSPs) in non-alcoholic fatty liver disease (NAFLD): from molecular mechanisms to therapeutic avenues

被引:1
|
作者
Nie, Zhenwang [1 ]
Xiao, Congshu [1 ]
Wang, Yingzi [2 ]
Li, Rongkuan [1 ]
Zhao, Fangcheng [1 ]
机构
[1] Dalian Med Univ, Dept Infect Dis, Affiliated Hosp 2, Dalian, Peoples R China
[2] Dalian Med Univ, Int Med Dept, Hosp 2, Dalian, Peoples R China
基金
英国科研创新办公室;
关键词
HSP60; HSP70; HSP90; GRP78; NAFLD; Molecular mechanisms; Therapeutic strategies; ENDOPLASMIC-RETICULUM-STRESS; LIPID-ACCUMULATION; MOUSE MODEL; HEPATOCYTES; INHIBITION; EXPRESSION; PATHWAYS; CELLS;
D O I
10.1186/s40364-024-00664-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-alcoholic fatty liver disease (NAFLD), a spectrum of liver conditions characterized by fat accumulation without excessive alcohol consumption, represents a significant global health burden. The intricate molecular landscape underlying NAFLD pathogenesis involves lipid handling, inflammation, oxidative stress, and mitochondrial dysfunction, with endoplasmic reticulum (ER) stress emerging as a key contributor. ER stress triggers the unfolded protein response (UPR), impacting hepatic steatosis in NAFLD and contributing to inflammation, fibrosis, and progression to NASH and eventually hepatocellular carcinoma (HCC). Heat shock proteins (HSPs), including small HSPs such as HSP20 and HSP27, HSP60, HSP70, GRP78, and HSP90, are integral to cellular stress responses. They aid in protein folding, prevent aggregation, and facilitate degradation, thus mitigating cellular damage under stress conditions. In NAFLD, aberrant HSP expression and function contribute to disease pathogenesis. Understanding the specific roles of HSP subtypes in NAFLD offers insights into potential therapeutic interventions. This review discusses the involvement of HSPs in NAFLD pathophysiology and highlights their therapeutic potential. By elucidating the molecular mechanisms underlying HSP-mediated protection in NAFLD, this article aims to pave the way for the development of targeted therapies for this prevalent liver disorder.
引用
收藏
页数:28
相关论文
共 50 条
  • [31] Current therapeutic strategies in non-alcoholic fatty liver disease
    Dowman, J. K.
    Armstrong, M. J.
    Tomlinson, J. W.
    Newsome, P. N.
    DIABETES OBESITY & METABOLISM, 2011, 13 (08) : 692 - 702
  • [32] Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Vizzutti, Francesco
    Arena, Umberto
    Nobili, Valerio
    Tarquini, Roberto
    Trappoliere, Marco
    Laffi, Giacomo
    Marra, Fabio
    Pinzani, Massimo
    ANNALS OF HEPATOLOGY, 2009, 8 (02) : 89 - 94
  • [33] Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease
    Leamy, Alexandra K.
    Egnatchik, Robert A.
    Young, Jamey D.
    PROGRESS IN LIPID RESEARCH, 2013, 52 (01) : 165 - 174
  • [34] Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives
    Yu, Xiao-Dong
    Wang, Jiong-Wei
    BIOCHEMICAL PHARMACOLOGY, 2022, 202
  • [35] Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Yao, Pengyu
    Liu, Yajuan
    MOLECULES, 2023, 28 (01):
  • [36] Autophagy and Non-Alcoholic Fatty Liver Disease
    Lavallard, Vanessa J.
    Gual, Philippe
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [37] Non-alcoholic fatty liver disease proteomics
    Rodriguez-Suarez, Eva
    Duce, Antonio M.
    Caballeria, Juan
    Martinez Arrieta, Felix
    Fernandez, Estefania
    Gomara, Carolina
    Alkorta, Nere
    Ariz, Usue
    Luz Martinez-Chantar, M.
    Lu, Shelly C.
    Elortza, Felix
    Mato, Jose M.
    PROTEOMICS CLINICAL APPLICATIONS, 2010, 4 (04) : 362 - 371
  • [38] Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)
    Alwahsh, Salamah Mohammad
    Gebhardt, Rolf
    ARCHIVES OF TOXICOLOGY, 2017, 91 (04) : 1545 - 1563
  • [39] Glucocorticoids and non-alcoholic fatty liver disease
    Woods, Conor P.
    Hazlehurst, Jonathon M.
    Tomlinson, Jeremy W.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2015, 154 : 94 - 103
  • [40] Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
    Rampche de Carvalho, Sylene Coutinho
    Cartaxo Muniz, Maria Tereza
    Vieira Siqueira, Maria Deozete
    Forte Siqueira, Erika Rabelo
    Gomes, Adriana Vieira
    Silva, Karina Alves
    Luma Bezerra, Lais Carvalho
    D'Almeida, Vania
    Marques Souza de Oliveira, Claudia Pinto
    Beltrao Pereira, Leila Maria M.
    NUTRITION JOURNAL, 2013, 12